Equity Overview
Price & Market Data
Price: $1.72
Daily Change: +$0.05 / 2.91%
Daily Range: $1.68 - $1.74
Market Cap: $115,422,544
Daily Volume: 6,726
Performance Metrics
1 Week: -60.52%
1 Month: -70.62%
3 Months: -74.96%
6 Months: -67.45%
1 Year: 51.82%
YTD: -74.35%
Company Details
Employees: 56
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.